CJC-1295 + Ipamorelin: The Two-Receptor Research Blend Explained

The per-component specification for the blend as supplied is listed on the product page. Note the nearly five-fold mass difference between the components — relevant to how a chromatogram of this blend reads, covered below.

The natural signal for this arm is GHRH, whose first 29 residues — GRF(1-29) — retain full receptor activity and became the standard scaffold for analogue engineering. Native GRF(1-29) has a serious laboratory limitation: it is degraded within minutes, with the DPP-4 enzyme clipping its N-terminus as the primary route. CJC-1295's backbone answers this with four targeted substitutions (positions 2, 8, 15, and 27 of the sequence), each chosen to block a specific degradation pathway while preserving GHRH-receptor agonism — a textbook case of stability engineering on a natural sequence (Jetté L, et al. Endocrinology. 2005;146(7):3052–3058).

The DAC distinction, precisely: "DAC" stands for Drug Affinity Complex — a maleimidopropionic-acid linker on a C-terminal lysine that covalently bonds to cysteine-34 of serum albumin, tethering the peptide to the blood's most abundant carrier protein and radically extending its persistence in circulation models. CJC-1295 with DAC carries that linker; the No DAC form in this blend is the bare tetrasubstituted 29-residue analogue — same receptor pharmacology, no albumin anchor. The two forms are frequently confused in market listings, and the difference is a covalent chemical modification, not a branding distinction. The GHRH receptor itself is a class B GPCR signaling predominantly through Gs, raising intracellular cAMP in its target cells (Mayo KE. Mol Endocrinol. 1992;6(10):1734–1744).

Ipamorelin comes from an entirely different lineage: the growth-hormone-secretagogue series developed from met-enkephalin-derived leads, arriving at a five-residue synthetic peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂, ~712 Da) that includes non-natural and D-form residues — one reason for its stability relative to natural sequences. Its receptor is GHS-R1a, the receptor later matched to the endogenous ligand ghrelin: a class A GPCR signaling through Gq, phospholipase C, IP₃, and intracellular calcium (Howard AD, et al. Science. 1996;273(5277):974–977).

What made ipamorelin notable in the published characterization work is selectivity: in the original in vitro and animal assays it activated its target receptor with potency comparable to earlier secretagogues while showing markedly less activity on the off-axis endpoints those earlier compounds disturbed — the reason it is frequently described in the literature as the selectivity benchmark of its class (Raun K, et al. Eur J Endocrinol. 1998;139(5):552–561). The full single-compound treatment is at Ipamorelin.

The design logic is receptor complementarity on one axis. The GHRH receptor and GHS-R1a are expressed on the same target-cell population but are different receptor classes running different second-messenger programs — Gs/cAMP for the GHRH arm, Gq/calcium for the ghrelin arm. Published mechanistic work established that engaging both arms produces signaling interplay that neither produces alone, including the observation that GHS-class compounds also act within the hypothalamic circuitry that governs the axis, not only on the end cell. For in vitro work, that means the blend allows a single fixed-ratio preparation to probe cAMP-arm, calcium-arm, and combined responses in the same model system — the two-receptor experiment in one vial. This is the same complementarity logic behind the other catalog blends, applied to a receptor pair instead of a mechanism pair; the comparison article on multi-receptor incretin design covers the equivalent idea in a different peptide family.

• Two identities, five-fold mass spread. Mass spectrometry must confirm a ~712 Da pentapeptide containing non-natural residues alongside a ~3,368 Da 29-mer — well-separated masses that make identity assignment clean when testing is actually performed.
• Distinct chromatographic behavior. The size and hydrophobicity gap means well-separated peak families in HPLC; per-component purity is read from assigned peaks, not a single main-peak figure.
• No-DAC verification. Because the DAC and No-DAC forms differ by a defined covalent modification with a large mass signature, mass spectrometry directly distinguishes them — the analytical answer to the market's most common confusion about this compound.
• Ratio confirmation. As with every fixed-ratio blend, peak areas per lot are the check on the stated component ratio.

HEEZ Research supplies CJC-1295 + Ipamorelin as a lyophilized preparation with independent third-party HPLC and mass-spectrometry testing; Certificates of Analysis are published on product pages as testing is completed — review the report before you order. Current specifications are on the CJC-1295 + Ipamorelin product page.